CN110384699A - Ccr3-抑制剂的用途 - Google Patents

Ccr3-抑制剂的用途 Download PDF

Info

Publication number
CN110384699A
CN110384699A CN201910406245.7A CN201910406245A CN110384699A CN 110384699 A CN110384699 A CN 110384699A CN 201910406245 A CN201910406245 A CN 201910406245A CN 110384699 A CN110384699 A CN 110384699A
Authority
CN
China
Prior art keywords
eosinophilic
alkyl
chloride
compound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910406245.7A
Other languages
English (en)
Chinese (zh)
Inventor
M·C·尼文斯
T·博伊苏
R·戈格尔
P·赛斯尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evergreen Springs
Original Assignee
Evergreen Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110384699(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evergreen Springs filed Critical Evergreen Springs
Publication of CN110384699A publication Critical patent/CN110384699A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
CN201910406245.7A 2012-04-03 2013-04-02 Ccr3-抑制剂的用途 Pending CN110384699A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937.2 2012-04-03
EP12162937 2012-04-03
CN201380016333.7A CN104220073A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380016333.7A Division CN104220073A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途

Publications (1)

Publication Number Publication Date
CN110384699A true CN110384699A (zh) 2019-10-29

Family

ID=48040249

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910406245.7A Pending CN110384699A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途
CN201380016333.7A Pending CN104220073A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380016333.7A Pending CN104220073A (zh) 2012-04-03 2013-04-02 Ccr3-抑制剂的用途

Country Status (28)

Country Link
US (5) US20130261153A1 (cg-RX-API-DMAC7.html)
EP (3) EP4389217A3 (cg-RX-API-DMAC7.html)
JP (2) JP2015512432A (cg-RX-API-DMAC7.html)
KR (5) KR20220132012A (cg-RX-API-DMAC7.html)
CN (2) CN110384699A (cg-RX-API-DMAC7.html)
AU (1) AU2013245027B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014023795B1 (cg-RX-API-DMAC7.html)
CA (1) CA2869269C (cg-RX-API-DMAC7.html)
CL (1) CL2014002523A1 (cg-RX-API-DMAC7.html)
CY (1) CY1123222T1 (cg-RX-API-DMAC7.html)
DK (1) DK2833884T3 (cg-RX-API-DMAC7.html)
EA (1) EA032263B1 (cg-RX-API-DMAC7.html)
ES (2) ES2987267T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20201165T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051648T2 (cg-RX-API-DMAC7.html)
IL (1) IL234262A (cg-RX-API-DMAC7.html)
IN (1) IN2014DN06989A (cg-RX-API-DMAC7.html)
LT (1) LT2833884T (cg-RX-API-DMAC7.html)
MX (1) MX2014011786A (cg-RX-API-DMAC7.html)
NZ (1) NZ628882A (cg-RX-API-DMAC7.html)
PH (1) PH12014502239A1 (cg-RX-API-DMAC7.html)
PL (1) PL2833884T3 (cg-RX-API-DMAC7.html)
PT (1) PT2833884T (cg-RX-API-DMAC7.html)
RS (1) RS60665B1 (cg-RX-API-DMAC7.html)
SI (1) SI2833884T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000499T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013149986A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406082B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
EP3449866B1 (en) 2016-11-24 2021-10-20 Kirishima Seiko Co., Ltd. Orthodontic appliance
US11382907B2 (en) * 2017-04-05 2022-07-12 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using CCR3-inhibitors
EA201992356A1 (ru) * 2017-04-05 2020-03-23 Алкахест Инк. Способ и композиция для лечения заболевания, связанного с сетчаткой глаза, с использованием ингибитора ccr3
CA3076017A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and compositions for treating pruritus, xerosis, and associated disease using ccr3-inhibitors
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
US12692301B2 (en) 2020-06-11 2026-07-28 Alkahest Inc. Methods of improving retina-associated disease outcome using CCR3-inhibitors
CA3221177A1 (en) 2021-11-01 2023-05-04 Meghan Kerrisk Campbell Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
GB2361704C (en) * 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115836A1 (en) * 2009-04-08 2010-10-14 Boehringer Ingelheim International Gmbh Substituted piperidines as ccr3 antagonists

Also Published As

Publication number Publication date
KR20250133980A (ko) 2025-09-09
US20170319567A1 (en) 2017-11-09
AU2013245027B2 (en) 2017-10-12
ES2987267T3 (es) 2024-11-14
KR20220132012A (ko) 2022-09-29
BR112014023795A2 (cg-RX-API-DMAC7.html) 2017-06-20
PT2833884T (pt) 2020-08-26
EP4389217A3 (en) 2024-08-28
NZ628882A (en) 2016-05-27
SI2833884T1 (sl) 2020-10-30
EA201401083A1 (ru) 2015-03-31
CN104220073A (zh) 2014-12-17
US20130261153A1 (en) 2013-10-03
JP2018080183A (ja) 2018-05-24
ES2811554T3 (es) 2021-03-12
WO2013149986A1 (en) 2013-10-10
PL2833884T3 (pl) 2020-11-02
BR112014023795A8 (pt) 2017-10-10
EP4389217A2 (en) 2024-06-26
JP2015512432A (ja) 2015-04-27
HUE051648T2 (hu) 2021-03-29
MX2014011786A (es) 2014-12-05
KR20200044988A (ko) 2020-04-29
DK2833884T3 (da) 2020-08-10
IL234262A (en) 2017-10-31
US20200375971A1 (en) 2020-12-03
KR20140144200A (ko) 2014-12-18
LT2833884T (lt) 2020-09-10
CA2869269C (en) 2020-06-30
HRP20201165T1 (hr) 2020-12-11
AU2013245027A1 (en) 2014-09-11
EP3763369B1 (en) 2024-02-28
EP2833884B1 (en) 2020-05-20
CL2014002523A1 (es) 2015-01-23
BR112014023795B1 (pt) 2021-09-08
EA032263B1 (ru) 2019-05-31
CA2869269A1 (en) 2013-10-10
PH12014502239A1 (en) 2014-12-15
SMT202000499T1 (it) 2020-11-10
EP2833884A1 (en) 2015-02-11
RS60665B1 (sr) 2020-09-30
CY1123222T1 (el) 2021-10-29
EP3763369A1 (en) 2021-01-13
US20150099783A1 (en) 2015-04-09
ZA201406082B (en) 2019-01-30
KR20210063481A (ko) 2021-06-01
IN2014DN06989A (cg-RX-API-DMAC7.html) 2015-04-10
US20160081998A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
EP2833884B1 (en) Use of ccr3-inhibitors
JP6700332B2 (ja) Ｃｃｒ３アンタゴニストを含む医薬製剤
CN110650740A (zh) 使用ccr3抑制剂治疗视网膜相关疾病的方法和组合物
HK40015701A (en) Use of ccr3-inhibitors
WO2016006621A1 (ja) Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物
JP5162161B2 (ja) 炎症性疾患の予防または治療剤
CN101415425B (zh) 甘油三酯降低剂和高胰岛素血症改善剂
US20080139615A1 (en) Combination of a hypnotic agent and r (+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40015701

Country of ref document: HK